Magnesium-containing oxytocin formulations and methods of use
Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
1. A method for treating pain, wherein the pain is a head or facial pain, a neck pain, a shoulder pain, or a pain in the upper extremities, comprising administering to a subject in need thereof an effective dose of an oxytocin peptide and a magnesium salt, wherein the oxytocin peptide is administered via craniofacial mucosal administration, and wherein the molar ratio between the dose of the oxytocin peptide administered and the dose of magnesium ions administered is between about 1:800 and about 1:30000.
2. The method of claim 1 , wherein the oxytocin peptide is administered via intranasal administration.
3. The method of claim 1 , wherein the effective dose of the oxytocin peptide is about 0.5 μg to about 2000 μg.
4. The method of claim 1 , wherein the effective dose of the magnesium salt provides about 50 μg to about 68 mg of magnesium.
5. The method of claim 1 , wherein the effective dose of the oxytocin peptide and the magnesium salt comprises about 15 μg to about 120 μg of the oxytocin peptide administered in an aqueous solution containing about 1.1% to about 1.6% (w/v) of magnesium.
6. The method of claim 1 , wherein the effective dose of the oxytocin peptide and the magnesium salt comprises about 66 μg of the oxytocin peptide administered in an aqueous solution containing about 1.36% magnesium.
7. The method of claim 1 , wherein the pain is a chronic pain, an acute pain, or an episodic pain.
8. The method of claim 1 , wherein the pain is a trigeminal nerve-associated pain or a cervical nerve-associated pain.
9. The method of claim 1 , wherein the pain is a migraine headache.
10. The method of claim 1 , wherein the oxytocin peptide is human oxytocin (SEQ. ID NO:1).
11. A composition comprising an oxytocin peptide and a magnesium salt, wherein the composition is contained in a device for craniofacial mucosal administration, and wherein the molar ratio between the oxytocin peptide in the composition and the magnesium ions in the composition is between about 1:800 and about 1:30000.
12. The composition of claim 11 , wherein the oxytocin peptide is human oxytocin (SEQ. ID NO:1).
13. The composition of claim 11 , wherein the composition is a liquid formulation comprising between about 0.01 mg/mL and about 16 mg/mL of the oxytocin peptide.
14. The composition of claim 13 , wherein the liquid formulation comprising between about 0.15 mg/mL and about 1.5 mg/mL of the oxytocin peptide.
15. The composition of claim 11 , wherein the composition is a liquid formulation comprising the magnesium salt in an amount to provide between about 3 mg/mL and about 30 mg/mL of magnesium.
16. The composition of claim 15 , wherein the liquid formulation comprising between about 11 mg/mL and about 15 mg/mL of magnesium.
17. The composition of claim 11 , further comprises one or more excipients, vehicles, emulsifiers, stabilizers, preservatives, mucosal adhesives, antibacterial agents, buffers, and/or other additives.
18. The composition of claim 11 , wherein the composition has a pH of about 4.5.
19. The composition of claim 11 , wherein the composition is contained in a device for intranasal administration.
20. The composition of claim 19 , wherein the device for intranasal administration is a nasal pump apparatus comprising a reservoir bottle attached to a pump actuator or a reservoir bottle attached to an aerosolizer.
21. A method for treating pain comprising administering to a subject in need thereof an effective dose of the composition of claim 11 and a pharmaceutically acceptable carrier.
22. A kit comprising the composition of claim 11 and a packaging.
23. The method of claim 1 , wherein the molar ratio between the dose of the oxytocin peptide administered and the dose of magnesium ions administered is between about 1:800 and about 1:20000.
24. The composition of claim 11 , wherein the molar ratio between the oxytocin peptide in the composition and the magnesium ions in the composition is between about 1:800 and about 1:20000.